Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Queensland Health
Fish and Richardson
QuintilesIMS
Moodys
McKesson
Baxter
Johnson and Johnson
Medtronic

Generated: June 25, 2018

DrugPatentWatch Database Preview

OLEPTRO Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Oleptro patents expire, and when can generic versions of Oleptro launch?

Oleptro is a drug marketed by Angelini Pharma and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and four patent family members in thirty-three countries.

The generic ingredient in OLEPTRO is trazodone hydrochloride. There are thirteen drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the trazodone hydrochloride profile page.
Drug patent expirations by year for OLEPTRO
Medical Subject Heading (MeSH) Categories for OLEPTRO
Synonyms for OLEPTRO
1,2,4-Triazolo(4,3-a)pyridin-3(2H)-one, 2-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-, monohydrochloride
1,2,4-triazolo[4,3-a]pyridin-3(2H)-one hydrochloride
1,2,4-Triazolo[4,3-a]pyridin-3(2H)-one, 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-, monohydrochloride
1,2,4-Triazolo[4,3-a]pyridin-3(2H)-one,2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-,hydrochloride (1:1)
1,4-Triazolo[4,3-a]pyridin-3(2H)-one, 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-, monohydrochloride
19666-36-5
2-(3-(4-(3-Chlorophenyl)-1-piperazinyl)propyl)-s-triazolo(4,3-a)pyridin-3(2H)-one HCl
2-(3-(4-(3-Chlorophenyl)piperazin-1-y)propyl)-1,2,4-triazolo(4,3-a)pyridine-3(2H)-one hydrochloride
2-(3-(4-(3-chlorophenyl)piperazin-1-yl)propyl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one hydrochloride
2-(3-(4-(3-Chlorophenyl)piperazin-1-yl)propyl)-1,2,4-triazolo(4,3-a)pyridin-3(2H)-one hydrochloride
2-(3-(4-(m-Chlorophenyl)-1-piperazinyl)propyl)-s-triazolo(4,3-a)pyridin-3(2H)-one monohydrochloride
2-[3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl]-
2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one hydrochloride
2-[3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl]-1,2,4-triazolo[4,3-a]pyridin-3(2H)-one hydrochloride
2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one hydrochloride
2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one;hydrochloride
2-[3-[4-(m-Chlorophenyl)-1-piperazinyl]propyl]-s-triazolo[4,3-a]pyridin-3(2H)-one monohydrochloride
2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-2H,3H-[1,2,4]triazolo[4,3-a]pyridin-3-one hydrochloride
2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one hydrochloride
2-{3-[4-(3-chlorophenyl)piperazinyl]propyl}-4-hydro-1,2,4-triazolino[4,3-a]pyr idin-3-one, chloride
25332-39-2
332T392
4CA-1276
6E8ZO8LRNM
A813950
A817789
AB2000676
AC-6779
AC1L1Y2P
AC1Q3BFE
AF 1161
AF-1161
AK-51734
AKOS015897762
AN-9680
Apo-Trazodone
Azona
BC215367
Bimaran
C19H22ClN5O.HCl
C19H23Cl2N5O
CAS-25332-39-2
CCG-40299
CHEBI:9655
CHEMBL1200798
CPD000058520
CS-2592
CT0209
CTK4F5497
D00820
Desyrel
Desyrel (TN)
Devidon
DSSTox_CID_24626
DSSTox_GSID_44626
DSSTox_RID_80361
DTXSID8044626
EINECS 243-216-2
EINECS 246-855-5
EU-0101159
FT-0659024
HE067225
HMS1568L06
HMS1922G09
HSDB 7048
HY-B0478
I13-027
J-015941
J10153
Jsp005028
K-6661
KB-831
KS-00000ZWU
KS-5100
LP01159
LS-156736
MCULE-3098459714
MFCD00079603
MLS000069698
MLS000758230
MLS001148260
MLS001424009
Molipaxin
MolPort-001-684-664
NC00046
NCGC00016035-02
NCGC00016035-13
NCGC00094420-01
NCGC00094420-02
NCGC00094420-03
NCGC00094420-04
NCGC00256807-01
NCGC00261844-01
NSC 292811
NSC-292811
NSC-758393
NSC292811
NSC758393
Opera_ID_850
Pharmakon1600-01503121
Pragmazone
Prestwick_478
PubChem15888
s-Triazolo(4,3-a)pyridin-3(2H)-one, 2-(3-(4-(m-chlorophenyl)-1-piperazinyl)propyl)-, monohydrochloride
s-Triazolo(4,3-a)pyridin-3(2H)-one, 2-(3-(4-(m-chlorophenyl)-1-piperazinyl)propyl)-,monohydrochloride
S-Triazolo[4, 2-[3-[4-(m-chlorophenyl)-1-piperazinyl]propyl]-, monohydrochloride
S-Trizolo[4, 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-, hydrochloride
S2582
SAM001247045
SC-16187
SCHEMBL61754
SMR000058520
SPECTRUM1503121
ST2407780
ST51015149
T 6154
Thombran
Tombran
Tox21_110286
Tox21_110286_1
Tox21_302685
Tox21_501159
Trazodone (hydrochloride)
Trazodone Hcl
Trazodone hydrochloride
Trazodone hydrochloride (Desyrel)
Trazodone hydrochloride (JAN/USP)
Trazodone hydrochloride [USAN:JAN]
Trazodone hydrochloride [USAN:USP:JAN]
Trazodone Hydrochloride 1.0 mg/ml in Methanol (as free base)
Trazodone hydrochloride, >=99% (HPLC), powder
Trazodone hydrochloride, United States Pharmacopeia (USP) Reference Standard
Tritico
Triticum
UNII-6E8ZO8LRNM
VA11904
WLN: T56 ANVNNJ C3- AT6N DNTJ DR CG &GH
Z1550675462

US Patents and Regulatory Information for OLEPTRO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Angelini Pharma OLEPTRO trazodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022411-001 Feb 2, 2010 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Angelini Pharma OLEPTRO trazodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022411-002 Feb 2, 2010 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Angelini Pharma OLEPTRO trazodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022411-001 Feb 2, 2010 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Angelini Pharma OLEPTRO trazodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022411-001 Feb 2, 2010 DISCN Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Paragraph IV (Patent) Challenges for OLEPTRO
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Extended-release Tablets 150 mg and 300 mg ➤ Subscribe 2010-10-18

Non-Orange Book US Patents for OLEPTRO

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,439,866 Trazodone composition for once a day administration ➤ Sign Up
8,414,919 Sustained drug release composition ➤ Sign Up
8,962,019 Sustained drug release composition ➤ Sign Up
8,314,236 Trazodone and trazodone hydrochloride in purified form ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
UBS
McKesson
Chubb
Healthtrust
US Department of Justice
Accenture
Baxter
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.